{
    "symbol": "BNTX",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-27 15:34:05",
    "content": " In addition to the approvals of our original COVID-19 vaccine, we received several approvals and authorizations of the original Omicron BA.4-5 adapted bivalent vaccine booster, including an FDA, EUA and EC approval for 5 to 11 years of age and an FDA EUA as a third 3 mg dose in the free dose primary series and a single booster dose at least 2 months after completion of primary vaccination with free doses of our original COVID-19 vaccine for children 6 months through 4 years of age."
}